Histone deacetylases 1 and 2 inhibition suppresses cytokine production and osteoclast bone resorption in vitro

Kent Algate, David Haynes, Tracy Fitzsimmons, Ornella Romeo, Florence Wagner, Edward Holson, Robert Reid, David Fairlie, Peter Bartold, Melissa Cantley

Research output: Contribution to journalArticle

Abstract

The regulation of epigenetic factors is an emerging therapeutic target of immune function in a variety of osteolytic pathologies. Histone deacetylases (HDAC) modify core histone proteins and transcriptional processes, in addition to nonhistone protein activity. The activated immune response in rheumatoid arthritis, periodontitis, and prosthetic implant particle release stimulates the catabolic activity of osteoclasts. In this study, we investigated the effects of novel therapeutic agents targeting HDAC isozymes (HDAC 1, 2, and 5), previously shown to be upregulated in inflammatory bone disorders, in cytokine-stimulated human monocytes and osteoclasts in vitro. Inhibiting HDAC 1 and 2 significantly reduced gene expression of IL-1β, TNF, MCP-1, and MIP-1α in TNF-stimulated monocytes, while suppressing secretions of IL-1β, IL-10, INF-γ, and MCP-1 (P <.05). Osteoclast formation and bone resorption were also significantly diminished with HDAC 1 and 2 inhibition, through reduced NFATc1 expression and osteoclast specific target genes, TRAF6, CTR, TRAP, and Cathepsin K (P <.05). Similar trends were observed when inhibiting HDAC 1 and to a lesser extent, HDAC 2, in isolation. However, their combined inhibition had the greatest anti-inflammatory and antiosteoclastic effects. Targeting HDAC 5 had minimal effects on these processes investigated in this study, whereas a broad acting HDACi, 1179.4b, had widespread suppressive outcomes. This study demonstrates that targeting HDACs is a potent and effective way of regulating the inflammatory and catabolic processes in human monocytes and osteoclasts. It also demonstrates the importance of targeting individual HDACs with an overall aim to improve efficiency and reduce any potential off target effects.

LanguageEnglish
Pages244-258
Number of pages15
JournalJournal of Cellular Biochemistry
Volume121
Issue number1
DOIs
Publication statusPublished - 1 Jan 2020

Keywords

  • bone loss
  • epigenetics
  • histone deacetylases (HDAC)
  • inflammation
  • osteoclasts
  • tumor necrosis factor (TNF)

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Algate, Kent ; Haynes, David ; Fitzsimmons, Tracy ; Romeo, Ornella ; Wagner, Florence ; Holson, Edward ; Reid, Robert ; Fairlie, David ; Bartold, Peter ; Cantley, Melissa. / Histone deacetylases 1 and 2 inhibition suppresses cytokine production and osteoclast bone resorption in vitro. In: Journal of Cellular Biochemistry. 2020 ; Vol. 121, No. 1. pp. 244-258.
@article{e47c82a39da944b490dcedab1d1978c7,
title = "Histone deacetylases 1 and 2 inhibition suppresses cytokine production and osteoclast bone resorption in vitro",
abstract = "The regulation of epigenetic factors is an emerging therapeutic target of immune function in a variety of osteolytic pathologies. Histone deacetylases (HDAC) modify core histone proteins and transcriptional processes, in addition to nonhistone protein activity. The activated immune response in rheumatoid arthritis, periodontitis, and prosthetic implant particle release stimulates the catabolic activity of osteoclasts. In this study, we investigated the effects of novel therapeutic agents targeting HDAC isozymes (HDAC 1, 2, and 5), previously shown to be upregulated in inflammatory bone disorders, in cytokine-stimulated human monocytes and osteoclasts in vitro. Inhibiting HDAC 1 and 2 significantly reduced gene expression of IL-1β, TNF, MCP-1, and MIP-1α in TNF-stimulated monocytes, while suppressing secretions of IL-1β, IL-10, INF-γ, and MCP-1 (P <.05). Osteoclast formation and bone resorption were also significantly diminished with HDAC 1 and 2 inhibition, through reduced NFATc1 expression and osteoclast specific target genes, TRAF6, CTR, TRAP, and Cathepsin K (P <.05). Similar trends were observed when inhibiting HDAC 1 and to a lesser extent, HDAC 2, in isolation. However, their combined inhibition had the greatest anti-inflammatory and antiosteoclastic effects. Targeting HDAC 5 had minimal effects on these processes investigated in this study, whereas a broad acting HDACi, 1179.4b, had widespread suppressive outcomes. This study demonstrates that targeting HDACs is a potent and effective way of regulating the inflammatory and catabolic processes in human monocytes and osteoclasts. It also demonstrates the importance of targeting individual HDACs with an overall aim to improve efficiency and reduce any potential off target effects.",
keywords = "bone loss, epigenetics, histone deacetylases (HDAC), inflammation, osteoclasts, tumor necrosis factor (TNF)",
author = "Kent Algate and David Haynes and Tracy Fitzsimmons and Ornella Romeo and Florence Wagner and Edward Holson and Robert Reid and David Fairlie and Peter Bartold and Melissa Cantley",
year = "2020",
month = "1",
day = "1",
doi = "10.1002/jcb.29137",
language = "English",
volume = "121",
pages = "244--258",
journal = "Journal of Cellular Biochemistry",
issn = "0730-2312",
publisher = "Wiley-Liss Inc.",
number = "1",

}

Algate, K, Haynes, D, Fitzsimmons, T, Romeo, O, Wagner, F, Holson, E, Reid, R, Fairlie, D, Bartold, P & Cantley, M 2020, 'Histone deacetylases 1 and 2 inhibition suppresses cytokine production and osteoclast bone resorption in vitro', Journal of Cellular Biochemistry, vol. 121, no. 1, pp. 244-258. https://doi.org/10.1002/jcb.29137

Histone deacetylases 1 and 2 inhibition suppresses cytokine production and osteoclast bone resorption in vitro. / Algate, Kent; Haynes, David; Fitzsimmons, Tracy; Romeo, Ornella; Wagner, Florence; Holson, Edward; Reid, Robert; Fairlie, David; Bartold, Peter; Cantley, Melissa.

In: Journal of Cellular Biochemistry, Vol. 121, No. 1, 01.01.2020, p. 244-258.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Histone deacetylases 1 and 2 inhibition suppresses cytokine production and osteoclast bone resorption in vitro

AU - Algate, Kent

AU - Haynes, David

AU - Fitzsimmons, Tracy

AU - Romeo, Ornella

AU - Wagner, Florence

AU - Holson, Edward

AU - Reid, Robert

AU - Fairlie, David

AU - Bartold, Peter

AU - Cantley, Melissa

PY - 2020/1/1

Y1 - 2020/1/1

N2 - The regulation of epigenetic factors is an emerging therapeutic target of immune function in a variety of osteolytic pathologies. Histone deacetylases (HDAC) modify core histone proteins and transcriptional processes, in addition to nonhistone protein activity. The activated immune response in rheumatoid arthritis, periodontitis, and prosthetic implant particle release stimulates the catabolic activity of osteoclasts. In this study, we investigated the effects of novel therapeutic agents targeting HDAC isozymes (HDAC 1, 2, and 5), previously shown to be upregulated in inflammatory bone disorders, in cytokine-stimulated human monocytes and osteoclasts in vitro. Inhibiting HDAC 1 and 2 significantly reduced gene expression of IL-1β, TNF, MCP-1, and MIP-1α in TNF-stimulated monocytes, while suppressing secretions of IL-1β, IL-10, INF-γ, and MCP-1 (P <.05). Osteoclast formation and bone resorption were also significantly diminished with HDAC 1 and 2 inhibition, through reduced NFATc1 expression and osteoclast specific target genes, TRAF6, CTR, TRAP, and Cathepsin K (P <.05). Similar trends were observed when inhibiting HDAC 1 and to a lesser extent, HDAC 2, in isolation. However, their combined inhibition had the greatest anti-inflammatory and antiosteoclastic effects. Targeting HDAC 5 had minimal effects on these processes investigated in this study, whereas a broad acting HDACi, 1179.4b, had widespread suppressive outcomes. This study demonstrates that targeting HDACs is a potent and effective way of regulating the inflammatory and catabolic processes in human monocytes and osteoclasts. It also demonstrates the importance of targeting individual HDACs with an overall aim to improve efficiency and reduce any potential off target effects.

AB - The regulation of epigenetic factors is an emerging therapeutic target of immune function in a variety of osteolytic pathologies. Histone deacetylases (HDAC) modify core histone proteins and transcriptional processes, in addition to nonhistone protein activity. The activated immune response in rheumatoid arthritis, periodontitis, and prosthetic implant particle release stimulates the catabolic activity of osteoclasts. In this study, we investigated the effects of novel therapeutic agents targeting HDAC isozymes (HDAC 1, 2, and 5), previously shown to be upregulated in inflammatory bone disorders, in cytokine-stimulated human monocytes and osteoclasts in vitro. Inhibiting HDAC 1 and 2 significantly reduced gene expression of IL-1β, TNF, MCP-1, and MIP-1α in TNF-stimulated monocytes, while suppressing secretions of IL-1β, IL-10, INF-γ, and MCP-1 (P <.05). Osteoclast formation and bone resorption were also significantly diminished with HDAC 1 and 2 inhibition, through reduced NFATc1 expression and osteoclast specific target genes, TRAF6, CTR, TRAP, and Cathepsin K (P <.05). Similar trends were observed when inhibiting HDAC 1 and to a lesser extent, HDAC 2, in isolation. However, their combined inhibition had the greatest anti-inflammatory and antiosteoclastic effects. Targeting HDAC 5 had minimal effects on these processes investigated in this study, whereas a broad acting HDACi, 1179.4b, had widespread suppressive outcomes. This study demonstrates that targeting HDACs is a potent and effective way of regulating the inflammatory and catabolic processes in human monocytes and osteoclasts. It also demonstrates the importance of targeting individual HDACs with an overall aim to improve efficiency and reduce any potential off target effects.

KW - bone loss

KW - epigenetics

KW - histone deacetylases (HDAC)

KW - inflammation

KW - osteoclasts

KW - tumor necrosis factor (TNF)

UR - http://www.scopus.com/inward/record.url?scp=85067858949&partnerID=8YFLogxK

U2 - 10.1002/jcb.29137

DO - 10.1002/jcb.29137

M3 - Article

VL - 121

SP - 244

EP - 258

JO - Journal of Cellular Biochemistry

T2 - Journal of Cellular Biochemistry

JF - Journal of Cellular Biochemistry

SN - 0730-2312

IS - 1

ER -